Natixis Investment Managers International Gilead Sciences, Inc. Transaction History

Natixis Investment Managers International

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $862,683 - $971,639	14,946 Added 23.75%	77,871 $4.81 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $3.64 Million - $4.57 Million	62,925 New	62,925 $3.74 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $17.1 Million - $22.3 Million	-282,744 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $2.88 Million - $3.19 Million	40,440 Added 16.69%	282,744 $21.8 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $471,612 - $550,117	7,269 Added 3.09%	242,304 $17.2 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $11.5 Million - $14 Million	157,305 Added 202.37%	235,035 $17.7 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $1.28 Million - $1.5 Million	-17,921 Reduced 18.74%	77,730 $5.57 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $946,804 - $1.12 Million	13,130 Added 15.91%	95,651 $7.75 Million
Q2 2017 Aug 14, 2017	BUY	N/A	82,521	82,521 $5.84 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.